论文部分内容阅读
河南单病种限价在全省400多家医院隆重推进,这种政府主导的改革试验,在当前寻求医疗体制改革突破和破解“看病难、看病贵”困局中,似乎让人看到了一丝亮光。单病种限价真的是一剂良药吗?本刊特派河南调查组采访发现,较之其它省市的单病种限价模式,河南的操作手法更具改良意味；较之省内以往的民间“松散试验”,河南二级以上医疗机构的全省联动也更有实质意义。然而,并非一气呵成的按病种收费管理方案,在盘根错节的利益均衡中,再度折射出中国医疗收费改革的尴尬与艰辛。即使如此,河南省正在酝酿在单病种限价基础之上,将进一步推进单病种定价。也许,围绕该项目改革试验的利弊争论也将会继续下去。我们试图给出更趋向客观的视角：即在当前全球实施的医疗收费模式中,按项目收费的后付制、总定额预付制以及按病种单元服务付费制,三种模式,究竟哪个更具有生命力,更适合中国?
Henan single-species price limit in the province more than 400 hospitals to promote the reform of this government-led pilot in the current medical system to seek breakthroughs in reform and break the “see a doctor difficult to see expensive” dilemma, it seems that people see a trace Bright light. Single disease limit is really a good medicine it? Journal survey of Henan correspondent found that compared with other provinces and cities single disease limit model, Henan practices more improved means; compared to the province’s previous Folk “loose test”, Henan province two or more medical institutions in the province linkage is more substantive. However, it is not the one-size-fits-all management plan for fee-based fees that once again reflects the awkwardness and hardship of reforming China’s medical fees and charges. Even so, Henan Province is brewing on the basis of a single disease limit, will further promote the pricing of single disease. Perhaps, the pros and cons of the reform experiment around the project will also continue. We are trying to give a more objective perspective: that in the current global health care fee model, pay-per-item post-pay system, the total fixed prepayment system and pay by disease unit service system, which three models, which are more Vitality, more suitable for China?